Funds and ETFs Bio-Rad Laboratories, Inc.

Equities

BIO

US0905722072

Medical Equipment, Supplies & Distribution

Real-time Estimate Cboe BZX 03:21:42 2024-04-29 pm EDT 5-day change 1st Jan Change
276.5 USD +0.19% Intraday chart for Bio-Rad Laboratories, Inc. -1.04% -14.15%

ETFs positioned on Bio-Rad Laboratories, Inc.

Name Weight AuM 1st Jan change Investor Rating
1.90% 2 M€ +6.77%
1.01% 16 M€ -7.06%
0.76% 2 M€ -.--%
0.46% 18 M€ +3.79% -
0.43% 92 M€ +0.06% -
0.14% 9 M€ -.--% -
0.09% 8 M€ +3.41% -
0.09% 33 M€ +0.25% -
0.09% 18 M€ +4.28% -
0.09% 5 M€ -72.95% -
0.07% 736 M€ +6.91%
0.07% 9 M€ +2.75% -
0.04% 27 M€ +17.28% -
0.03% 559 M€ +14.30% -
0.03% 1,848 M€ +18.39% -
0.03% 6 M€ +17.98% -
0.03% 125 M€ +4.55% -
0.03% 273 M€ -.--%
0.03% 655 M€ -.--% -
0.03% 1,174 M€ +23.54%
0.03% 2,658 M€ +10.32% -
0.03% 61 M€ +17.30% -
0.02% 23 M€ -.--% -
0.02% 786 M€ -.--%
0.02% 35 M€ +10.02% -
0.02% 0 M€ 0.00% -
Bio-Rad Laboratories, Inc. is specialized in the development, manufacturing and marketing of products used in life sciences research, clinical diagnostics and analytical chemistry. Net sales break down by activity as follows: - manufacture of clinical diagnostic tests and automated test systems (51.8%). The group also offers test kits, quality control systems and related IT systems; - manufacture of reagents, equipment and instruments for biological research (48.1%): for the separation, identification and purification of chemical and biological substances (proteins, nucleic acids, bacteria, etc.) for the proteomics, genomics research, biopharmaceuticals, cell biology and food safety markets; - other (0.1%): in particular, manufacturing of analytical instruments. At the end of 2022, the Group has 16 production sites in the United States (5), Germany (3), France (2), China (2), Poland, the United Kingdom, Switzerland and Singapore. Net sales are distributed geographically as follows: the United States (41.2%), Europe (30.4%), Asia (22.8%) and other (5.6%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
6
Last Close Price
275.9 USD
Average target price
419.9 USD
Spread / Average Target
+52.17%
Consensus

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Equities
  3. BIO Stock
  4. Funds and ETFs Bio-Rad Laboratories, Inc.